期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

他汀类药物与肾脏损害 被引量：5

原文传递
导出
摘要 他汀是一类目前最强效的调脂药物，可用于患有肾脏疾病合并高脂血症的患者。有临床观察提示，他汀类药物通过纠正血脂代谢紊乱，可降低肾脏疾病患者发生缺血性心血管疾病如冠心病和缺血性脑卒中等危险；此外还有可能通过改变肾脏血液动力学或抑制炎症反应等作用，改善肾功能或延缓肾功能的恶化。但是，也有病例报道他汀类药物对肾脏可能有损害作用。
作者 赵水平
机构地区 中南大学湘雅二医院心血管内科
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2011年第3期198-199,共2页 Chinese Journal of Cardiology
关键词 他汀类药物 肾脏损害 缺血性心血管疾病 肾脏血液动力学 血脂代谢紊乱 缺血性脑卒中 抑制炎症反应 肾脏疾病
分类号 R692 [医药卫生—泌尿科学]
  • 相关文献

参考文献11

  • 1Van Zyk-Smit R,Firth JC,Duffield M,et al.Renal tubular toxicity of HMG-CoA reductase inhibitors.Nephrol Dial Transplant,2004,19:3176-3179.
  • 2Cheung BM,Lauder IJ,Lau CP,et al.Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes.Br J Clin Pharmacol,2004,15:640-651.
  • 3Jacobson TA.Statin safety:lessons from New Drug Applications for marketed statins.Am J Cardiol,2006,97 (Suppl 8A):44C-51C.
  • 4García Rodríguez LA,Herings R,Johansson S.Use of multiple international healthcare databases for the detection of rare drugassociated outcomes:a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins.Pharmacoepidemiol Drug Saf,2010,19:1218-1224.
  • 5Bertram LK,Christoph WW,Charles ON.An assessment of statin safety by nephrologists.Am J Cardiol,2006,97 (Suppl):82C-85C.
  • 6Fried LF,Orchard TJ,Kasiske BL.The effect of lipid reduction on renal disease progression:a meta-analysis.Kidney Int,2001,59:260-269.
  • 7Vidt DG,Cressman MD,Harris S,et al.Rosuvastatin-induced arrest in progression of renal disease.Cardiology,2004,102:52-60.
  • 8Sandhu S,Wiebe N,Fried LF,et al.Statins for improving renal outcomes:a meta-analysis.J Am Soc Nephrol,2006,17:2006-2016.
  • 9Ridker PM,MacFadyen J,Cressman M,et al.Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein:a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial.J Am Coll Cardiol,2010,55:1266-1273.
  • 10Deslypere JP,Delanghe J,Vermeulen A.Proteinuria as complication of simvastatin treatment.Lancet,1990,336:1453.

同被引文献45

  • 1田志,吴非飞,郑向清.瑞舒伐他汀与阿托伐他汀对冠状动脉支架术后患者的干预研究[J].中华临床医师杂志（电子版）,2011,5(20):6141-6143. 被引量：11
  • 2Rosuvastatin Registration Clinical Trial Group.Cardiovascular Institute and Fu Wai Hospital,Peking Union Medical College and Chinese Academy of Medical Science,Beijing 100037,China.瑞舒伐他汀治疗中国高胆固醇血症患者疗效和安全性的随机双盲多中心对照研究[J].中华心血管病杂志,2007,35(3):207-211. 被引量：117
  • 3Ribeiro S,Faria MD,Silva G,et al.Oxidized low-density lipoprotein and lipoprotein(a)levels in chronic kidney disease patients under hemodialysis:Influence of adiponectin and of a polymorphism in the apolipoprotein(.
  • 4Kanbay M,Turgut F.Statin treatment for dyslipidemia in CKD and renal transplantation:a review of the evidence[J].J Nephrol,2009,22:598-609.
  • 5Baigent C,Landray MJ,Reith C,et,al.The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease(Study of Heart and Renal Protection):a randomised placebocontrolled.
  • 6Sharp Collaborative Group.Study of Heart and Renal Protection(SHARP):randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among9,438patients with chronic kidney disease[J].Am Heart.
  • 7Van Zyk-Smit R,Firth JC,Marais AD,et al.Renal tubular toxicity of HMGCoA reductase inhibitors[J].Nephrol Dial Transplant,2004,19:31763179.
  • 8Jenkins M,Goldsmith D.Statins and kidney disease:is the study of heart and renal protection at the cutting edge of evidence[J].Curr Opin Cardiol,2012,27:429-440.
  • 9Bertram LK,Christoph WW.Charles ON.An assessment of statin safety by nephrologists[J].Am J Cardiol,2006,97:82-85.
  • 10Fried LF,Orchard TJ,Kasiske BL.The effect of lipid reduction on renal disease progression:a meta-analysis[J].Kidney Int,2001,59:260-269.

引证文献5

二级引证文献8

中华心血管病杂志
2011年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部